Literature DB >> 12494348

Two flavonols from Artemisa annua which potentiate the activity of berberine and norfloxacin against a resistant strain of Staphylococcus aureus.

Frank R Stermitz1, Lacey N Scriven, George Tegos, Kim Lewis.   

Abstract

Bioassay-guided fractionation of an extract of Artemisia annua L. (Asteraceae) was conducted in order to assess the possible presence in the plant material of inhibitors of bacterial multidrug resistance pumps. Fractions were tested for Staphylococcus aureus growth inhibition in the presence of a subinhibitory dose of the weak antibacterial alkaloid berberine. Active fractions yielded the flavones chrysosplenol-D and chrysoplenetin, which themselves had very weak growth inhibitory action, but which made a potent combination with berberine. In comparison with work on other flavonols, it is likely that potentiation is due to the inhibition of an S. aureus multidrug resistance (MDR) pump. These same two flavonols were earlier reported to potentiate the activity of artemisinin against Plasmodium falciparum.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12494348     DOI: 10.1055/s-2002-36347

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  24 in total

Review 1.  The biosynthesis of artemisinin (Qinghaosu) and the phytochemistry of Artemisia annua L. (Qinghao).

Authors:  Geoffrey D Brown
Journal:  Molecules       Date:  2010-10-28       Impact factor: 4.411

Review 2.  Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.

Authors:  Laura J V Piddock
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 3.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

4.  In vivo antiulcer activity, phytochemical exploration, and molecular modelling of the polyphenolic-rich fraction of Crepis sancta extract.

Authors:  Sherif S Ebada; Nariman A Al-Jawabri; Fadia S Youssef; Amgad Albohy; Sa'ed M Aldalaien; Ahmad M Disi; Peter Proksch
Journal:  Inflammopharmacology       Date:  2019-09-03       Impact factor: 4.473

Review 5.  Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2.

Authors:  Lindsay K Caesar; Nadja B Cech
Journal:  Nat Prod Rep       Date:  2019-06-19       Impact factor: 13.423

6.  Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis).

Authors:  Hiyas A Junio; Arlene A Sy-Cordero; Keivan A Ettefagh; Johnna T Burns; Kathryn T Micko; Tyler N Graf; Scott J Richter; Robert E Cannon; Nicholas H Oberlies; Nadja B Cech
Journal:  J Nat Prod       Date:  2011-06-10       Impact factor: 4.050

Review 7.  Microbial efflux pump inhibition: tactics and strategies.

Authors:  George P Tegos; Mark Haynes; J Jacob Strouse; Mohiuddin Md T Khan; Cristian G Bologa; Tudor I Oprea; Larry A Sklar
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

8.  Sarothrin from Alkanna orientalis is an antimicrobial agent and efflux pump inhibitor.

Authors:  Jessica R Bame; Tyler N Graf; Hiyas A Junio; R Owen Bussey; Scott A Jarmusch; Tamam El-Elimat; Joseph O Falkinham; Nicholas H Oberlies; Richard A Cech; Nadja B Cech
Journal:  Planta Med       Date:  2013-03-06       Impact factor: 3.352

9.  Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.

Authors:  Michael Wink; Mohamed L Ashour; Mahmoud Zaki El-Readi
Journal:  Front Microbiol       Date:  2012-04-23       Impact factor: 5.640

10.  Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation.

Authors:  Christina Kourtesi; Anthony R Ball; Ying-Ying Huang; Sanjay M Jachak; D Mariano A Vera; Proma Khondkar; Simon Gibbons; Michael R Hamblin; George P Tegos
Journal:  Open Microbiol J       Date:  2013-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.